/ Side by side
Semaglutide vs Tirzepatide
A neutral, side-by-side look at Semaglutide and Tirzepatide: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Semaglutide
Ozempic · Wegovy · Rybelsus
Full profile →Tirzepatide
Mounjaro · Zepbound
Full profile →| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~1 week | ~5 days |
| Common vial | 2, 3, 5, 10 mg | 5, 10, 15, 20, 30, 60 mg |
| Reference | Verified | Verified |
What is Semaglutide?
A GLP-1 receptor agonist, acylated for albumin binding and DPP-4 resistance, studied for glycemic control in type 2 diabetes and for weight management. Its long half-life supports once-weekly administration.
Sources
- FDA label: Ozempic (NDA 209637)
- FDA label: Wegovy (215256)
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration.
Sources
- FDA approvals: Mounjaro (2022), Zepbound (2023)
- Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.